• Deutsch
  • English
  • Français
  • Русский
  • Română
  • Español
  • Български

TauroLock™

Das antimikrobielle Katheter-Locksystem

From the ASN 2016, Philadelphia: TauroLock™-U25.000 vs. Citrate 4%

In a randomized controlled trial from Austria with 106 haemodialysis patients (Winnicki, W. and Sengoelge, G., JASN 2016,27:TH-OR 127) which was presented during the ASN meeting 2016 in Philadelphia a locking regimen with TauroLockTM-Hep500 twice weekly and TauroLockTM-U25.000 once weekly (before the long interval) was compared to 4% Citrate (CitraFlowTM) three times weekly.

The TauroLock 2+1 regimen was significantly superior to 4% Citrate in all aspects investigated:

 

TaurolockTM 2+1

4% Citrate

p-value

Catheter days

8982

6708

 

Catheter-related bloodstream infections (/1000 catheter days)

 

0.67

2.6

0.003

Catheter dysfunction (/1000 catheter days)

18.7

44.3

0.001

Alteplase intervention (/1000 catheter days)

3.8

38

0.001

The results of this study show that 4% Citrate is no alternative to TauroLockTM neither regarding infection prevention nor maintenance of patency.